Two micro organism working in concord present highly effective antitumor results. The method may rework therapy for immunocompromised sufferers.
A analysis group led by Professor Eijiro Miyako on the Japan Superior Institute of Science and Expertise (JAIST), working in collaboration with Daiichi Sankyo Co., Ltd. and the College of Tsukuba, has created a pioneering bacterial remedy for most cancers that operates independently of the immune system. This new method depends on a specifically designed microbial consortium referred to as AUN.
The idea of bacterial most cancers remedy dates again to 1868, when German doctor Busch reported that deliberately infecting a affected person with micro organism led to tumor regression. Later, in 1893, Dr. William Coley proposed bacterial injections as a therapy, laying the inspiration for most cancers immunotherapy. Over the previous 150 years, these early concepts developed into superior therapies equivalent to checkpoint inhibitors and CAR-T cells. Whereas efficient for some, these therapies all rely upon immune cell exercise, which limits their effectiveness in sufferers whose immune methods are weakened by chemotherapy or radiotherapy.
The brand new AUN remedy overcomes this problem by combining two naturally occurring bacterial strains:
- Proteus mirabilis (A-gyo), a microbe that thrives inside tumors
- Rhodopseudomonas palustris (UN-gyo), a photosynthetic bacterium
Mechanisms of tumor eradication
Working in shut cooperation, the “AUN” bacterial pair achieved exceptional tumor clearance in each mouse and human most cancers fashions, even below immunocompromised circumstances—all with out counting on immune cells. The remedy demonstrated robust biocompatibility and really restricted negative effects, notably stopping cytokine launch syndrome (CRS).
On this research, AUN’s potent antitumor exercise was pushed by a number of coordinated bacterial mechanisms, together with:
Concord between bacterial companions
Notably, UN-gyo capabilities as a regulatory associate solely when coexisting with A-gyo, serving to to suppress the pathogenicity of each strains whereas concurrently enhancing their tumor-specific cytotoxicity. This “cooperation of labor” mirrors the Japanese philosophical idea of “AUN”—good concord between opposites. It’s this delicate and dynamic interaction between the 2 bacterial species that unlocks the remarkable antitumor efficacy—a feat previously unattainable through conventional therapies.
“To accelerate the social implementation of this research, we are preparing to launch a startup and aim to begin clinical trials within six years,” said Professor Eijiro Miyako, lead author of the study.
“A new chapter in bacteria-based cancer therapy—pursued for over 150 years—is finally beginning.”
This revolutionary approach represents a paradigm shift for immunocompromised cancer patients. It offers a long-awaited therapeutic solution in cases where conventional immunotherapies fail—ushering in the dawn of truly immune-independent cancer treatment.
Reference: “Tumour-resident oncolytic bacteria trigger potent anticancer effects through selective intratumoural thrombosis and necrosis” by Seigo Iwata, Taisei Nishiyama, Matomo Sakari, Yuki Doi, Naoki Takaya, Yusuke Ogitani, Hiroshi Nagano, Keisuke Fukuchi and Eijiro Miyako, 5 August 2025, Nature Biomedical Engineering.
DOI: 10.1038/s41551-025-01459-9
Never miss a breakthrough: Join the SciTechDaily newsletter.
